Hospital operator Tenet Healthcare (NYSE: THC) will be reporting results tomorrow before the bell. Here’s what you need to know.
Tenet Healthcare missed analysts’ revenue expectations by 2% last quarter, reporting revenues of $5.07 billion, down 5.7% year on year. It was a mixed quarter for the company, with an impressive beat of analysts’ full-year EPS guidance estimates.
Is Tenet Healthcare a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Tenet Healthcare’s revenue to decline 4% year on year to $5.15 billion, a reversal from the 6.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $3.13 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Tenet Healthcare has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 2.1% on average.
Looking at Tenet Healthcare’s peers in the healthcare providers & services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. HCA Healthcare delivered year-on-year revenue growth of 5.7%, beating analysts’ expectations by 0.5%, and Centene reported revenues up 15.4%, topping estimates by 8.3%.
Read our full analysis of HCA Healthcare’s results here and Centene’s results here.
The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 5.6% on average over the last month. Tenet Healthcare is down 9.2% during the same time and is heading into earnings with an average analyst price target of $170.56 (compared to the current share price of $122.10).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
